Antibiogram of Pseudomonas aeruginosa Clinical Isolates Tested for Pan, Extensive and Multidrug Resistances

Background: Pseudomonas aeruginosa usually cause nosocomial infections with concurrent morbidity and mortality and is generally resistant to many antibiotics.

Aim: This study was aimed to determine the proportion of pan-drug-resistant (PDR), extensively drug-resistant (XDR), and multidrug-resistant (MDR) P. aeruginosa strains recovered from human samples.

Methodology: The retrospective study was conducted in the University of Nigeria Teaching Hospital Enugu in 2023. Clinical samples obtained from patients between October 2022 and April 2023 were analysed. A total of 100 Pseudomonas aeruginosa isolates recovered from 780 clinical samples were used. Standard microbiological techniques were used to identify and categorize the isolates. Antibiotic susceptibility pattern was determined using the Kirby Bauer disc diffusion method.

Results: Isolates recovered from wound was 38%, voided urine, catheter tip urine, ear swab, and high vaginal swab samples recorded 29%, 11%, 10% and 4%, respectively. Ceftazidime recorded the highest level of resistance (70.0%) and the least was Colistin (20%). Resistance patterns showed that 32(32.0%) bacterial strains were MDR, 68(68.0%) were XDR and no PDR was recorded.

Conclusions: For the best selection of empirical therapy, P. aeruginosa susceptibility monitoring is essential due to the high prevalence of antibiotic resistance. The resistance pattern raises the possibility of misuse of broad-spectrum antibiotics. Treatment for bacterial infections should be directed by the results of antimicrobial susceptibility tests.